New Transcription Factors and Their Role in Diabetes and Therapy

Advances in Molecular and Cellular Endocrinology

Edited by

  • Jacob Friedman, University of Colorado Health Sciences Center, Denver, CO, USA

This book contains contributions from some of the most eminent experts in the fields of genetics, biochemistry, and pathophysiology of diabetes. Through specific examples, with broad applications, this book provides a comprehensive look at how transcription factors may underline the pathogenetic mechanisms of diabetes and obesity. Volume 5 provides an overview of the status of the field, while also providing valuable information of practical utility to those who do not necessarily work in this field. The integration of basic biology with physiologically and clinically relevant proteins should provide the reader with a theoretical background to understanding the strategies for new potential therapeutic targets and their application to disease.
View full description


Endocrinologists, Biomedical researchers, Geneticists, Molecular and Cellular Biologists


Book information

  • Published: August 2006
  • Imprint: ELSEVIER
  • ISBN: 978-0-444-51158-4

Table of Contents

1. PPARs as therapeutic targets for treating diabetes and insulin resistance2. Genetic regulators of human obesity and diabetes3. NF-kb, insulin resistance and the actions of salicylates4. Wnt signaling and C/EBPs role in adipogenesis5. Regulation of hepatic gluconeogenesis C/EPBs6. Forkhead proteins and regulation of hepatic gene expression7. Control of mitochondrial biogenesis through PGC-18. Regulation of PGC-1 in humans in insulin resistance and diabetes: Functional implications9. FOXC2 controls resistance to obesity and Type II diabetes10. SREB-1C regulation of nutrient homeostasis and lipid accumulation11. GATA proteins as molecular gatekeeprs of the adipocyte12. Diabetes regulation of gene expression by CREB13. Molecular etiologies of MODY and other early-onset forms of diabetes14. Liver X receptors as potential drug targets for Diabetes and its disorders15. The potential therapeutic use of PPAR beta/delta agonists in lipid and glucose homeostasis16. Influences of new PPAR insulin sensitizers on the metabolic syndrome in Rhesus Monkeys17. PPARgamma and metabolism: Insights from the study of human genetic variants